Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
Päätekijät: | Mihaylova, B, Armitage, J, Briggs, A, Gray, A, Parish, S, Collins, R, Collaborati, H |
---|---|
Aineistotyyppi: | Conference item |
Julkaistu: |
2005
|
Samankaltaisia teoksia
-
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
Tekijä: Mihaylova, B, et al.
Julkaistu: (2005) -
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
Tekijä: Mihaylova, B, et al.
Julkaistu: (2006) -
N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
Tekijä: Emberson, J, et al.
Julkaistu: (2005) -
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
Tekijä: Armitage, J, et al.
Julkaistu: (2009) -
N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
Tekijä: Emberson, J, et al.
Julkaistu: (2005)